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Abstract
Introduction: Traditional approaches to clinical research have, as yet, failed to provide effective treatments for vascular
dementia (VaD). Novel approaches to collation and synthesis of data may allow for time and cost efficient hypothesis
generating and testing. These approaches may have particular utility in helping us understand and treat a complex
condition such as VaD.
Methods: We present an overview of new uses for existing data to progress VaD research. The overview is the result of
consultation with various stakeholders, focused literature review and learning from the group’s experience of successful
approaches to data repurposing. In particular, we benefitted from the expert discussion and input of delegates at the
9th International Congress on Vascular Dementia (Ljubljana, 16-18th October 2015).
Results: We agreed on key areas that could be of relevance to VaD research: systematic review of existing studies;
individual patient level analyses of existing trials and cohorts and linking electronic health record data to other
datasets. We illustrated each theme with a case-study of an existing project that has utilised this approach.
Conclusions: There are many opportunities for the VaD research community to make better use of existing data. The
volume of potentially available data is increasing and the opportunities for using these resources to progress the VaD
research agenda are exciting. Of course, these approaches come with inherent limitations and biases, as bigger datasets
are not necessarily better datasets and maintaining rigour and critical analysis will be key to optimising data use.
Keywords: Big data, Data, Clinical Trials, Cohort studies, Dementia, Electronic health records, Systematic review, Registries,
Vascular dementia
Background
Traditional approaches to clinical research, such as
the randomised controlled trial (RCT), have facilitated
major advances in our understanding and treatment
of common diseases. In the stroke field we now have
robust evidence for many aspects of acute care [1]. In
comparison evidence based interventions for preven-
tion and treatment of vascular dementia (VaD) are
relatively sparse [2].
Although there are few RCTs in VaD, data do exist.
There are several alternative sources and approaches to
data that could be used for time- and cost-efficient re-
search. Exploiting novel methods of data collation and
synthesis may allow us to develop the VaD evidence
base, where traditional study designs have failed to de-
liver. Repurposing existing resources to allow for original
research in VaD is aligned with current moves towards
improving research efficiency and reducing waste [3], a
theme of increasing importance to funders and peer
reviewers.
In this overview we describe a variety of approaches to
data, providing background and illustrate with case-
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studies. We will discuss a series of complementary re-
search methodologies (Table 1). We do not claim that
the overview is exhaustive and we recognise there is
a degree of overlap. The overview will keep a VaD
focus where possible, although the techniques dis-
cussed are applicable to many research areas. Some of
the research approaches are relatively new and for
some, as yet, there are no specific examples of their
application in the VaD field. In these situations we
take exemplars from other areas of research.
Methods
This paper is a result of a dynamic and iterative process.
The lead authors first reviewed the published literature and
identified key thematic areas. Organisations or research
groups working in these areas were identified and invited
to contribute. The consensus was further developed as a
key topic area of the International Congress on Vascular
Dementia in Ljubljana, Slovenia (16th – 18th October 2015).
Comments were collated following a plenary session and
open invitation workshop at the conference. Key stake-
holders met for a round table meeting and finalised the
content of the overview. Topic leads (MA, GDB, GM, TR,
RS) drafted each specific section of the overview with syn-
thesis and editing by ICVD data theme leads (FD, TQ). The
draft was shared with other researchers and centres who
expressed an interest, and subsequent discussion and revi-
sion continued until a final agreed text was reached.
Big data
The “big data” concept is a hot topic in contemporary
research but there is continuing debate over the mean-
ing of the phrase [4]. According to the Gartner group
definition, “big data” is characterized by the following
properties:
a) large data volume (“volume”)
b) heterogeneity and disparity of data (“variety”)
c) the speed with which data are being generated
(“velocity”)
d) quality and integrity of data (“veracity”)
The fourth “V” was added to illustrate the need for
critical assessment of the quality of data:
Under the rubric of big data we can consider various
information sources and various approaches to curation
and analysis. Data can be “big” in terms of breadth
(number of individuals, for example national data regis-
tries) or “big” in terms of depth (level of detail on each
individual, for example sophisticated neuroimaging).
Often data are “big” in both senses (for example a popu-
lation registry with multimodal data such as UK
Biobank).
Large data sets are being generated in traditional
spheres of science and health but also in many other as-
pects of everyday life, internet usage; social media; shop-
ping habits etc. The “omics” arena (a term used to
Table 1 Summary of methods and their potential strengths and weaknesses for data in VaD
Approach Potential strengths Potential limitations
Systematic review and meta-analysis - Methodology applicable to RCT, observational
studies and animal studies
- Pooling results increases power to detect modest
but clinically meaningful effects
- Identify early evidence of harms vs. benefits of
treatments and provide evidence-based
recommendations
- Quality of summary result is dependent on the
quality of the included studies
- Often substantial between study heterogeneity
- Not all available evidence is published and this
may give biased results
Individual patient level data from
completed trials
- Pooling data increases statistical power
- Greater opportunity and flexibility to explore new
research questions than traditional aggregate
meta-analysis
- RCT level quality control of source data with
standardised, validated, monitored data points
- Cost effective approach, saving resources and time
- Limited generalizability
- Risk of bias of different RCT populations
- Analyses restricted to available data
- Inconsistency in tools used to assess outcomes
may limit potential, this is a particular issue in
studies of cognition
Individual participant level data
from cohort studies
- Opportunity for large multicentre research platforms
- ‘last word’ science
- Strong epidemiological focus
- Limitations inherent to observational studies
- Reverse causality
- Confounding
Big data informatics - Large data volume – cohort size, registries
- Heterogeneity of data - multimodality
- Potential for semi-automated data analyses
- Patient data confidentiality to be protected
- Development of data sharing mechanisms
- Complex computational methods and support
required
Data linkage and use of routinely
recorded data
- Resource-efficient
- variety of differing data sources available, not solely
limited to traditional health settings
- Cross-sectional studies can turned into longitudinal, e.g.
follow up a cohort of people with dementia for hospital
admissions, death etc.
- Selection bias depending on type of data used
(e.g. hospital admissions)
- Quality of data might vary
- Non-standardised outcome measures
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describe the collection of scientific technologies that in-
vestigate the mechanisms of molecules and their interac-
tions within a cell) is an example of a potentially
transformative activity using large datasets. With the ad-
vent of Next Generation Sequencing (NGS) technolo-
gies, a new scale of data production has been reached:
sequencing one person's genome produces approxi-
mately 4 terabytes of raw data output.
The landscape is evolving and the combined effect of
technological advances (increasing capacity and decreas-
ing cost of data storage) and healthcare systems change
(increasing electronic recording of patient data) make
for a rich environment to facilitate big data research in
VaD. If we extrapolate what can be observed in immun-
ology and cancer biology, we should prepare for a tsu-
nami of data in dementia research in the near future.
Entire patient cohorts will be fully sequenced at reason-
able price and within days; we can expect very soon a
high resolution representation of genome variation in
large studies such as EPAD (European Prevention of
Alzheimer’s Dementia), ADNI (for Alzheimer´s Disease)
and PPMI (for Parkinson´s Disease).
At the same time, we see an urgent need to enhance
the interpretability of “big data” based on the current
state of knowledge. Technologies to extract and to rep-
resent essential knowledge are now mature enough to
allow for the rapid construction of knowledge-based
models for entire indication areas. Algorithms such as
“reverse causal reasoning” [5] allow for a rapid analysis
of whether a given data set represents the causal and
correlative relationship patterns in a knowledge-based
model. As a consequence, semi-automated data analysis
will be possible at large scale and high throughput,
matching essential requirements for big data processing
and analysis in the future.
We can expect that, in the near future, data produc-
tion at all levels - from the omics level to the clinical
and population level - will increase at the same rate in
dementia research as can be observed in other indication
areas. The need for increased interoperability of data,
and validation of data, will simultaneously increase, and
substantial effort will be required to cope not only with
the rapid growth of data volume, but also with the no-
torious lack of interoperability of data, information, and
knowledge. We will see more ambitious mining scenar-
ios in big data challenges in the future, and integrative
modelling and mining approaches.
Case-study: scientific and patent literature
These documents contain information in disparate for-
mats: unstructured semantic data (text); structured data
(tables); and graphically encoded information (chemical
structures and their interactions). From the Big Data
perspective, the literature data pools are incomplete and
of varying quality. Only a fraction of the more recent
biomedical peer reviewed literature offers unrestricted
access to machine-readable full text. Patent documents,
while freely available online, provide only scanned bit-
maps and/or raw optical character recognition output in
most cases, and their ontology does not readily integrate
with the corresponding peer review literature [6].
These deficiencies notwithstanding, the corpus of pub-
lished scientific information allows targeted as well as
parameter-free data mining projects that could reveal
not only unexpected risk factors and interactions that
are relevant for VaD, but could also uncover drug effects
and side effects that provide invaluable clues to the re-
development of known drugs and drug candidates. If lit-
erature mining is combined with mining patient-level
data from clinical trials and/or postmarketing side effect
data reports [7], drug repurposing research has almost
unlimited potential. It requires a multidimensional
approach that is based on two fundamental facts:
 All disorders are driven along molecularly defined
molecular pathways, which have interaction nodes
that can be modulated, often in multiple ways; and
 All drugs are multifunctional.
Provided that the biological pathways and their inter-
actions are understood, and that the pharmacological
activities of the drug compounds are known, therapeut-
ically meaningful new combinations can be identified
using either exploratory or targeted (“drill-down”) algo-
rithms, or most likely by their sequential application [8].
In VaD drug discovery, such efforts could be directed to-
wards identifying known compounds that interfere with
many critical points in the vicious cycle of cerebral small
vessel disease, reduced blood flow and metabolism and
neurological damage.
Systematic review and meta-analysis
An obvious, but to date underused, resource for VaD re-
search comes from synthesis of existing trial data.
Historically, the research community has been guilty of
pursuing research in areas where sufficient evidence is
available [9]. This is both inefficient and unethical and a
comprehensive review is a crucial first step in research.
Systematic review of the literature could be used to in-
form VaD research in a number of ways:
 Answering important research questions without
needing to do further primary research
 Identifying ‘knowledge gaps’ and so setting the research
agenda
 Informing sample size calculations for larger trials
 Identifying early evidence of harms and benefits of
treatments
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For the field of VaD research, scoping reviews by
Cochrane and other groups, suggest that there is a fairly
limited original research base on interventions for VaD.
Thus it seems unlikely that systematic review will pro-
vide definitive answers, but comprehensive and critical
synthesis of the available literature could assist in the
choice of interventions for assessment and in the design
of VaD trials.
Systematic review is not limited to human research.
Reviews of animal studies can inform the translational
medicine pathway. For example, a systematic review of
antidepressants in animal models of stroke showed re-
duction in infarct size and improvement in neurobeha-
vioural scores [10], consistent with the apparently
beneficial effects of selective serotonin reuptake inhibi-
tors on recovery after stroke [11] and supported meth-
odologically robust ongoing clinical trials testing
fluoxetine for stroke recovery [12]. Groups such as
CAMARADES (Collaborative Approach to Meta-
Analysis and Review of Animal Data from Experimental
Studies) have raised standards in systematic review of
animal studies.
Systematic review methodologies are also available
to facilitate reviews of observational studies, diagnos-
tic test accuracy and qualitative original research. For
some of these areas, guidance is emerging on best
practice in conduct, reporting and quality assessment.
These materials have had a general dementia focus
and will be just as applicable to VaD as to other
dementia syndromes [13–15].
A systematic review should be considered as an ex-
periment. There should be a clearly defined research
question and methods which are described in advance in
a protocol. Systematic reviews should have stated objec-
tives with pre-defined eligibility criteria for studies, ex-
plicit, reproducible methodology, comprehensive search
strategies that attempt to identify all studies (including
unpublished studies), assessment of the validity of the
findings of the included studies (including risk of bias
and generalisability), systematic presentation, and syn-
thesis of characteristics and findings and if possible, a
meta-analysis.
Case study – the Cochrane stroke and dementia
groups
Cochrane (formerly the Cochrane Collaboration) is an
international organisation of 37,000 contributors from
over 130 countries (http://www.cochrane.org). Cochrane
gathers and summarizes the best evidence from research
to help patients, clinicians and policy makers make in-
formed choices about treatments. During the past 20
years, Cochrane has transformed the way health deci-
sions are made.
Cochrane groups include healthcare subject-related re-
view groups, thematic networks, methodology groups
and regional centres located all over the world. There is
no Cochrane group exclusively for VaD research. The
topic is most aligned with the Cochrane Stroke Group
and the Cochrane Dementia and Cognitive Improvement
Group (CDCIG). Both groups are exemplars of how
Cochrane can produce clinically important outputs,
shape the research agenda and develop new ap-
proaches to data.
The CDCIG (http://dementia.cochrane.org) has over
200 reviews and a comprehensive, open-access register
of randomised controlled clinical trials or studies of
diagnostic tests in dementia treatment, prevention and
cognitive enhancement: ALOIS (http://www.medicine.
ox.ac.uk/alois/). CDCIG reviews with a VaD focus are
available [16] but numbers are modest in comparison to
Alzheimer’s disease dementia. The Cochrane Stroke
Group produces reviews on all aspects of stroke care.
The group has produced several reviews on the manage-
ment of cognitive deficits after stroke, an area that could
be considered part of the VaD remit [17]. These reviews
have demonstrated a paucity of trials, indicating that the
management of post-stroke cognitive impairment is an
important area for future research. The Cochrane Stroke
Group hosts DORIS (The Database of Research in
Stroke) which contains over 22,000 references to trials
in an easy to search study-based form.
Both the CDCIG and Stroke groups would welcome
expressions of interest to work on a synthesis of avail-
able data pertinent to VaD and related conditions.
Individual-patient level data from completed trials
Completed RCTs offer a rich source of high quality, in-
dividual patient level data on demographics, clinical fea-
tures, treatments and adverse events across a range of
time points. Yet, following trial completion and publica-
tion, raw datasets often reside in industry or academic
archives. If patient level data can be accessed and pooled
from a number of trials then the statistical power and
opportunity to explore new questions is increased sub-
stantially. For a field like VaD where we have limited
original research, improving the value of the available
datasets becomes even more important.
Re-use of anonymised RCT data has several benefits:
 RCT data are standardised, high quality, validated,
and robustly monitored
 The reuse of existing RCT data is cost effective.
 Development of definitive studies can be expedited
by using existing data, saving time and money. In
contrast, prospective data collection on a similar
population and subsequent analyses can add years to
the research timeline.
Doubal et al. BMC Neurology  (2017) 17:72 Page 4 of 10
The principal limitation of collating individual patient
level data is that clinical trial datasets do not usually
provide a representative sample. This is a particular
problem in VaD and where trials are available they are
often limited to a specific subgroup, for example mild
cognitive impairment. Furthermore any analyses will be
restricted to those data and endpoints that have been
collected in trials. This can be problematic when trialists
use a variety of assessments for an outcome, a particular
issue in VaD research where a plethora of tools are used
to measure cognition [18].
Case study – the virtual international stroke trials
archive (VISTA) and VISTA-cognition
The Virtual International Stroke Trials Archive (VISTA)
[19] was developed with the aim of collating and provid-
ing access to clinical stroke trial data for novel analyses.
The resource is home to more than 82,000 anonymised
individual patients’ data and has facilitated more than 80
peer-reviewed publications on a range of topics. The
VISTA resource has been used to pilot novel elements
of RCT design, develop and validate prognostic tools
and optimise endpoints for future RCTs [20–22].
The VISTA founding members recognised that post
stroke cognitive impairment is a major issue but has
been relatively under-studied [23] and so have created a
resource to lodge data on prospective stroke studies with
a neuropsychological focus (VISTA-Cognition). Estab-
lished in summer 2015, the resource already holds data
on 2,422 individuals across 8 studies, with commitments
to contribute data from a further 6 large studies (http://
www.vista.gla.ac.uk/index.php/vista-cognition). Following
approval by the relevant Steering Committee, anonymised
datasets are compiled and sent to the investigator for ana-
lyses. The first dedicated outputs from VISTA-Cognition
are awaited but studies from the VISTA resource are
already advancing our understanding of VaD [24].
Completed and on-going cohort studies
Large-scale observational cohort studies have informed
much of our understanding of VaD. Despite increasing
financial investment in routinely collected data and their
potential for linkage, investigator-led (field-based) cohort
studies still have an important research role both for sin-
gle- (‘discovery’ science) and multi-study analyses (‘defini-
tive' science). Ongoing work is bringing together existing
cohort studies with dementia ascertainment to create a
platform for research as well as identifying existing co-
horts that may not have a (vascular) dementia focus but
could still contain data of relevance to VaD research. An
example is Dementia Platforms UK (DPUK) a collabor-
ation between academic centres and industry, established
by the Medical Research Council, with a remit of sharing
data and catalysing translational dementia research.
An ideal cohort substrate for VaD research would be a
longitudinal, population-based study with repeated mea-
sures of cognition, clinical (including detailed vascular
assessment) and sociodemographic data. A recent Joint
Programme for Neurodegenerative Disease (JPND)
research consortium has identified over 90 cohorts
(600,000 participants) with data that could be used to
explore the vascular contribution to cognitive decline
[25]. Even with relatively lengthy follow-up and detailed
cognitive examination the number of incident VaD diag-
nosis in population cohorts is likely to be modest and
statistical methods for modelling cognitive decline may
need to be employed [26].
The approach of pooling raw observational data across
studies, with some refinements, was originally used in
advancing our understanding of the importance of blood
pressure, cholesterol, and weight for chronic disease risk
[27, 28]. Although, as yet, these cohorts have not been
used in a VaD context, more recently, this work has been
extended to focus on psychological risk markers. This
work has found that even moderate levels of distress are
associated with elevated mortality [29]; personality types is
unrelated to cancer risk [30] and reduced height, a marker
of early life environmental insults, and socioeconomic dis-
advantage is linked to an elevated risk of all dementias
combined [31]. This pooling of cohort studies is limited
by the perennial shortcomings of observational studies
themselves; chiefly, confounding and reverse causality.
Case study – the UCL Scottish Health Survey and
the Health Survey for England collaboration
The Health and Social Surveys Research Group within
the Department of Epidemiology and Public Health at
University College London has, for over 20 years, been
responsible for designing, implementing, and curating
data from the Scottish Health Survey and the Health
Survey for England. These are a series of annual, inde-
pendent, geographically representative health examina-
tions of adults from the general population living in
private households in Scotland and England. Crucially
for the purposes of individual-participant meta-analysis,
the methodology of these studies is near-identical [32, 33].
The prospective element to the study has been pro-
vided by the linkage of consenting study members to
the National Health Service mortality register. This
process of prospective, repeated phenotyping of a defined
population with opportunity to link to other health re-
cords is urgently required to progress the VaD research
field.
Informatics and electronic patient records
The adoption of electronic patient records (EPRs) in
routine clinical care is generating hitherto unseen
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volumes of data both in scale (case numbers) and depth
(quantity of information on individual cases) [34]. The
use of EPRs for research is in its infancy and its focus
has been an overly narrow one on technical solutions;
however, a more pressing need is to develop expertise in
data use, so that the data resources are not wasted on
questions for which they are not best suited. There is
mileage in an EPR based approach to VaD but the best
use of these data requires some consideration.
While there may be some utility for EPR data in VaD risk
factor studies, these questions are often better answered
using traditional research designs, which are less impeded
by missing and/or biased data. Furthermore, a risk factor
whose rarity requires the very large samples offered by
EPRs for its detection may be of little clinical relevance,
and rare but important risk factors may best investigated
with other experimental designs. Where EPR datasets are
strongest is in allowing naturalistic follow-up of sizeable pa-
tient cohorts receiving routine interventions. Therefore
they would be particularly valuable for evaluating VaD dis-
ease course (e.g. who gets better, who gets worse, or cogni-
tive trajectories post diagnosis) and determinants of
response to intervention (e.g. who benefits most, who is
most vulnerable to adverse effects) although confounding
by indication needs to be carefully considered. Indeed, in
these scenarios, EPR datasets are often the platform of
choice, because bespoke clinical cohorts (i.e. those specific-
ally recruited and examined) are limited in size and general-
isability, and combined RCT samples even more so.
Having been a resource for some time in primary care,
large EPR datasets have begun to accumulate in special-
ist services, including those providing dementia care
[35]. Applications relevant to VaD have included an
evaluation of relative response to acetyl cholinesterase
inhibitor treatment [36] and mortality associated with
antipsychotic use [37]. Natural language processing tech-
niques offer the potential for expanding the depth of
data for analysis through ‘unlocking’ information which
is traditionally recorded in text rather than structured
fields in the record. [38] However, arguably the most
pressing challenge for EPR-derived research in dementia
is the diversity of services providing care. For example, a
typical ‘patient journey’ might involve a detailed assess-
ment for diagnosis in specialist care, and useful cross-
sectional data, but then discharge is relatively rapid back
to primary care, followed by sporadic contacts with spe-
cialist care (e.g. for behavioural symptom management)
and acute care (for dementia-related and/or incidental
hospitalisations). If the main application of EPR re-
search, as previously argued, is to evaluate the course
and progression of a disorder, this is limited in dementia
because only specialist care records are likely to contain
direct evaluations of dementia status, such as measures
of cognitive function.
So what are the potential solutions? Increased dementia-
specific routine data might accrue in future if a clinical ra-
tionale emerges for recording these; however, this is cur-
rently not a foreseeable scenario. Proxy measures of disease
progression might also be derived from multiple data
sources, although this requires comprehensive data linkage
across primary, acute, and specialist care, as well as poten-
tially social care. Wearable or home-based devices might be
used to track progression, although remain experimental
and, again, need to demonstrate clinical applicability.
Finally, shared records systems allowing patient and
carer input might provide novel opportunities for inform-
ative feedback on ‘real world’ outcomes.
In Sweden the development of quality registries to im-
prove quality of care for different disorders has been
very successful and has led to clear improvements in
care. EPR data in Sweden are not developed enough to
extract research data, and throughout the country many
different EPR systems are used. The quality registries
collect data from the health care system and outcomes
are often quality indicators developed by national guide-
lines for diseases in question. The Swedish Dementia
registry, SveDem, registers dementia disorders at the
time of diagnosis with a yearly follow-up. The registry
has a national coverage of about 40% of all incident de-
mentia cases in Sweden [39]. Using personal identifica-
tion numbers, SveDem can be linked to other registries
such as the national patient registry, the national drug
prescription registry, deaths collated to national popula-
tion registries, and other quality registries or biomarker
databases [40, 41]. The sheer size of the registry
(>65,000 patients with dementia) has made it possible,
for example, to study mortality between different de-
mentia disorders [42].
Data linkage and use of routinely recorded data
“Each person in the world creates a Book of Life. This
Book starts with birth and ends with death. Its pages are
made up of the records of the principal events in life.
Record linkage is the name given to the process of as-
sembling the pages of this Book, into a volume. The
Book has many pages for some and is but a few pages in
length for others.” [43].
Assembling an individual’s contacts with health ser-
vices – and often non-health institutions such as social
care, education, or criminal justice – is a resource-
efficient way to collate a large volume of data which
have already been recorded for other purposes. The
power of this methodology is that it can turn cross-
sectional studies into longitudinal ones, whether data
linkage is used to follow up a cohort of people with de-
mentia [31, 44], or whether it is used to identify incident
dementia in a general population sample [45]. This ap-
proach is particularly attractive for a condition such as
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VaD, where an individual is likely to be assessed and
treated by a variety of health and social care agencies
with greater and lesser involvement of differing disci-
plines as the disease progresses.
Using already collected data allows for large scale
studies at a fraction of the cost and time that would
be required to run a prospective outcomes study,
while having data available across whole populations
allows for investigation of uncommon conditions. The
greater use and sophistication of information technol-
ogy in healthcare allows further opportunity to use
routine clinical data for research at a national or even
international level.
There are a number of limitations to this methodology
which must be borne in mind, particularly when data
linkage is used to identify people with dementia. If hos-
pital admission records are used, there is immediate se-
lection bias because not everyone will be admitted to
hospital. Once admitted to hospital, dementia only
seems to be recorded on discharge about half the time
[45]. However, individuals who are admitted multiple
times stand more chance of their diagnosis being re-
corded on at least one occasion. Again, these issues are
even more problematic if the focus is a specific dementia
subtype such as VaD, as often this level of granularity of
diagnosis is not routinely captured. Multiple admissions
are more common in those with dementia diagnoses.
Furthermore, one cannot often infer the date of diagno-
sis, other than to state that dementia occurrence and
diagnosis must have occurred before the first record
mentioning dementia. Perhaps more importantly one
cannot infer the timing of diagnosis, for example an
early diagnosis made in primary care versus a diagnosis
of late stage dementia when a person is resident in a
care-home. Timing of dementia diagnosis is crucial to
understanding potential direction of causation in studies
looking at risk factors for dementia. If no unique identi-
fier is available for each individual then probabilistic
matching algorithms with an arbitrary threshold must be
used to ensure that all the records associated with that
person truly refer to them.
Death records have previously been thought to be in-
adequate for use in epidemiological studies [46] but rates
of reporting are improving. Importantly, because people
with dementia often die of something else, it is essential
to look for ‘any mention’ of dementia on the death cer-
tificate, rather than merely looking at the underlying
cause of death. Thus, in a tertiary referral memory clinic
sample, 72% of people with robustly diagnosed dementia
had their diagnosis correctly recorded on their death
certificate [44]. However, the codes recorded are often
non-specific dementia rather than diagnostic subtype.
Thus, all-cause dementia ascertained from data linkage
is likely to be a reasonably robust outcome, as are rare
subtypes such as Fronto Temporal Dementia which are
likely to be correct if they are recorded. In contrast, more
common subtypes such as Alzheimer’s dementia and
VaD are probably less robustly identified from routinely
recorded data at the moment. This issue may be less
important than previously thought, as the aetiological
classification of dementia is evolving and concepts of
pure Alzheimer's Disease and pure VaD are now consi-
dered less useful in older adults with dementia. One
specific area in which this technique might have utility is
in post-stroke dementia since acute stroke is arguably
better identified, with high accuracy and clear times of
diagnosis. Thus, a cohort of stroke survivors could be
identified to follow up or, possibly, people who have
dementia recorded following some record of a stroke
could be found.
Case-study – using routinely recorded data in
Scotland
Scotland, along with certain other European countries,
is well placed for exploiting data linkage as a means
to progress VaD research. Everyone born or living in
Scotland is issued with a unique identifier (the 10-
digit Community Health Index number [CHI]). The
CHI number is issued to label all encounters within
NHS Scotland and is also used for national datasets
such as mortality (death certification). National re-
sources that also use CHI labelling include the NHS
Central Register which notifies deaths with up to six
causes of death recorded and the Scottish Morbidity
Records (SMR). SMR includes various domains, for
example records of discharges from acute hospitals in
Scotland (SMR01), mental health hospitals in Scotland
(SMR04) and Scottish cancer registrations (SMR06).
Each discharge record contains up to 6 diagnoses,
coded using International Classification of Diseases
codes. Broader aspects of health and social care are
being recorded with CHI labelling, for example
admission to care-home and, in certain parts of
Scotland, use of home-care services. The healthcare
system in Scotland, where there is little use of exclu-
sive private healthcare and almost all medical encoun-
ters are within the NHS, ensures comprehensive
population coverage that is CHI labelled. In theory,
using CHI linkage offers the potential to create a
pan-national cohort. However, the lack of a specific
electronic patient record for cognitive impairment
and dementia undermines the capacity to utilise the
otherwise excellent data in Scotland.
Standardised outcome measurement
A recurring theme in our discussion of data driven VaD
research is around the validity of the data availability
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when there is significant variation in the types and defi-
nitions used for VaD outcome measurement. The Inter-
national Consortium for Health Outcome Measurement
(ICHOM) is a not-for-profit organization that was
co-founded by leaders from The Karolinska Institute,
The Boston Consulting Group, and Harvard Business
School and is uniquely grounded in a solid theoretical
framework: value based health care [47, 48]. ICHOM’s
goal is to develop Standard Sets of outcomes, because a
standardised approach aids comparisons of outcomes
across cultures, countries and healthcare systems.
ICHOM believe this approach allows teams of health
professionals to learn from one another, and enables in-
stitutions to use data to benchmark against each other,
foster dialogue around variations in outcomes and learn
from the best. ICHOM brings together leading health-
care professionals, registry leaders, outcome measure-
ment experts and patient advocates to develop globally
agreed Standard Sets of outcome measures that matter
most to patients, for the world’s most burdensome med-
ical conditions. The ICHOM methodology for creating
Standard Sets is well-established, and brings together a
literature review, review of existing registries, modified
Delphi consensus processes, patient focus groups, an
open consultation, and an expert working group that in-
cludes patients at every stage. ICHOM have recently de-
veloped and published the Dementia Standard Set,
which is being piloted across institutions to identify the
‘best-in-class’ outcomes which can then drive health care
improvements (http://www.ichom.org/medical-condi-
tions/dementia/).
Conclusion
This review demonstrates approaches to data that may as-
sist in elucidating the causes and determining the treat-
ment of VaD (an area of significant unmet need). “Big
data” approaches can either use routinely collected clinical
data (where clear challenges exist in ensuring complete
capture of all health care records) or can be adopted to
mine other available data to devise and answer novel
questions. A caution with all these approaches is that they
are reliant on the original data and study design. Big data
does not necessarily mean better data.
There has been recent major financial investment by
research agencies in the use of new approaches to data
and considerable excitement in the scientific commu-
nity as a result It has been said that the utility of new
approaches to data will be most apparent in those
areas where traditional approaches to clinical research
have still to deliver effective treatments. In this regard
the VaD research community should embrace the new
opportunities and make full use of all the available
resources.
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